Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5958509 | 0.85 | CA12 (0.46) | CA12CA1CA9CA2MGLL | |
| SCHEMBL1101234 | 0.82 | CA12 (0.58) | CA12CA1CA9CA2MGLL | |
| SCHEMBL6252070 | 0.81 | GRIN2D (0.41) | CA12CA1CA9CA2MGLL | |
| SCHEMBL8393428 | 0.81 | CA12 (0.50) | CA12CA1CA9CA2MGLL | |
| SCHEMBL8393427 | 0.81 | CA12 (0.50) | CA12CA1CA9CA2MGLL | |
| SCHEMBL29333 | 0.81 | ZDHHC20 (0.45) | CA12CA1CA9CA2MGLL | |
| SCHEMBL5980787 | 0.80 | CA12 (0.63) | CA12CA1CA9CA2MGLL | |
| SCHEMBL11085445 | 0.80 | ZDHHC20 (0.47) | CA12CA1CA9CA2MGLL | |
| SCHEMBL5980795 | 0.80 | CA12 (0.63) | CA12CA1CA9CA2MGLL | |
| SCHEMBL17956778 | 0.80 | CA12 (0.61) | CA12CA1CA9CA2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | claimed |
| WO-2023009500-A1 | PENTAAZA MACROCYCLIC RING COMPLEX FOR ENHANCED SURGICAL TREATMENT | GALERA LABS, LLC (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | GALERA LABS, LLC | 2022-07-21 | — | — | US | claimed |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | BIOSSIL INC. (CA) | 2022-04-21 | — | — | US | claimed |
| US-20210361701-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES FOR LOCAL DELIVERY | GALERA LABS, LLC | 2021-11-25 | — | — | US | claimed |
| US-5610293-A | TREATMENT OF INFLAMMATORY DISEASES, ISCHEMIC/REPERFUSION INJURY, STROKE, ATHERSCLEROSIS, HYPERTENSION | MONSANTO COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1997006824-A2 | BIOCONJUGATES OF MANGANESE COMPLEXES AND THEIR APPLICATION AS CATALYSTS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0758892-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0756495-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1997-02-05 | — | — | EP | claimed |
| WO-1996040658-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996039396-A1 | MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| JP-H08505622-A | — | — | 1996-06-18 | — | — | JP | claimed |
| WO-1995031197-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | claimed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361701-A1 | PENTAAZA MACROCYCLIC RING COMPLEXES FOR LOCAL DELIVERY | SI, APC, VIP | CA12 754/4885CA1 2022/4885CA9 2952/4885 |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | CA12 308/4885CA1 834/4885CA9 774/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | CA12 49/4885CA1 192/4885CA9 487/4885 |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | SOD1, MSH6, SLC30A6 | CA12 131/4885CA1 159/4885CA9 123/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CA12 497/4885CA1 1182/4885CA9 1260/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | CA12 497/4885CA1 1182/4885CA9 1260/4885 |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | CA12 453/4885CA1 1382/4885CA9 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.